Precigen Q4 2020 Earnings Report
Key Takeaways
Precigen reported Q4 2020 revenues of $19.3 million compared to $17.0 million in Q4 2019. The net loss from continuing operations was $39.7 million, or $(0.22) per basic share, compared to a net loss of $64.2 million, or $(0.41) per basic share in Q4 2019. Cash, cash equivalents, and short-term investments totaled $100.1 million as of December 31, 2020.
Accomplished anticipated 2020 clinical milestones despite pandemic challenges.
Strengthened balance sheet with a successful public offering while streamlining operations and reducing operating costs.
Initial data readouts from PRGN-3005 and PRGN-3006 UltraCAR-T® clinical trials demonstrated encouraging expansion, persistence, and clinical activity.
A PRGN-3006 UltraCAR-T patient achieved complete remission with incomplete hematologic recovery (CRi) per ELN criteria.
Precigen
Precigen
Precigen Revenue by Segment
Forward Guidance
2021 promises to be another transformative year for our company with important data readouts and trial initiations anticipated for our key programs.
Revenue & Expenses
Visualization of income flow from segment revenue to net income